Collaborations and License Agreements - Additional Information (Details)		1 Months Ended																	3 Months Ended									12 Months Ended
	Aug. 01, 2019 USD ($)	Feb. 28, 2022 USD ($)	Aug. 31, 2020 USD ($)	Sep. 30, 2019 USD ($)	May 31, 2019 USD ($)	Feb. 28, 2019 USD ($)	Dec. 31, 2018 USD ($)	Nov. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Feb. 28, 2018 USD ($)	Oct. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Dec. 31, 2016	Aug. 31, 2015 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2012 USD ($)	Mar. 31, 2010 USD ($)	Dec. 31, 2006 USD ($)	Dec. 31, 2021 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Sep. 30, 2020 USD ($)	Jun. 30, 2020 USD ($)	Mar. 31, 2020 USD ($)	Sep. 30, 2019 USD ($)	Dec. 31, 2021 USD ($) indication	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2015 USD ($)	Apr. 30, 2014 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Trade receivables, net																			$ 9,811,000				$ 0					$ 9,811,000	$ 0
Milestone payment to be received																			2,000,000									2,000,000
Revenues																			17,646,000	$ 15,173,000	$ 7,556,000	$ 1,920,000						42,295,000	6,019,000	$ 28,795,000
EUSA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development reimbursement received											$ 2,000,000	$ 4,000,000																			$ 2,500,000
Percentage of EUSA cost-sharing for TIVO-3 trial																															50.00%
Research and development reimbursement milestone																												20,000,000.0
Milestone payment to be received																			$ 2,000,000									2,000,000
Collaborations and license agreements, expected milestone receivable					$ 2,000,000	$ 2,000,000	$ 2,000,000	$ 2,000,000	$ 2,000,000	$ 2,000,000
Payments received in connection per indication																												$ 2,000,000
Eligible number of indications | indication																												3
Payments received in connection with additional indications																												$ 5,000,000
Potential payments received in connection with additional indications																												$ 335,000,000
Sublicense fee to earned milestone payments and royalties																			30.00%									30.00%
Collaborations and license agreements, potential future payment as percentage of certain amounts the Company receives under sublicense agreements																			30.00%									30.00%
Milestone payment																			$ 8,700,000									$ 8,700,000
Milestone payment subject to sublicense fees																			20,000,000									20,000,000
Allocation of upfront payment						$ 600,000		$ 600,000		$ 600,000
Revenues																												3,421,000	3,219,000	3,795,000
Deferred revenue recognized as collaboration and licensing revenue																			578,000				2,552,000					578,000	2,552,000
Transaction price																												12,500,000
Kyowa Kirin
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment																			0									0
Kyowa Kirin
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues				$ 25,000,000																				$ 2,800,000
Non refundable upfront payment																											$ 25,000,000
Milestone payment received			$ 2,800,000
Transaction price																								27,800,000
Development and Regulatory Milestone Events | St Vincent's Hospital Sydney Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Term after first sale														10 years
Termination notice period														6 months
Development and Regulatory Milestone Events | St Vincent's Hospital Sydney Limited | Subsequent Event
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment		$ 2,300,000
Maximum | Biogen Idec International GmbH
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalty payments															$ 50,000,000
Maximum | Development and Regulatory Milestone Events | St Vincent's Hospital Sydney Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognition milestone method milestone payables																			14,400,000									14,400,000
Partnership licensing and royalty revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues																			891,000	$ 855,000	$ 821,000	$ 854,000	886,000	$ 3,600,000	$ 749,000	$ 784,000		3,421,000	6,019,000	28,795,000
Partnership licensing and royalty revenue | EUSA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues																												1,447,000	1,245,000	861,000
License | Kyowa Kirin
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues																							$ 2,800,000					0	2,800,000
Opt In To Planned Phase Three Study | Minimum | EUSA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Eusa potential opt-In payment TIVO three trial																												8,700,000
Opt In To Planned Phase Three Study | Maximum | EUSA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development reimbursement potential opt-in payment																												20,000,000.0
Astra Zeneca Agreement | Astra Zeneca Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Trade receivables, net																			800,000									800,000
FOCAL study | Biodesix
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalty on future product sales, percentage of future licensing revenue																																25.00%
Required payment amount for agreement																																$ 2,500,000
FOCAL study | Minimum | Biodesix
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contribution percentage of clinical, regulatory, manufacturing and other costs																																50.00%
Licensing Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, one time milestone payment waived	$ 18,000,000.0
Collaborations and license agreements, expected milestone receivable																												390,700,000
Term of royalty payment obligations			10 years
Non refundable upfront payment	25,000,000
Milestone payment received			$ 2,800,000
Aggregate milestone payments																			$ 387,900,000									$ 387,900,000
Licensing Agreements | St Vincent's Hospital Sydney Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received														$ 1,500,000
Licensing Agreements | Kyowa Kirin
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment receivable				$ 25,000,000
Collaborations and license agreements, one time milestone payment waived	$ 18,000,000
Upfront payment received																		$ 5,000,000
Collaborations and license agreements, milestone payment																	$ 10,000,000
Licensing Agreements | Kyowa Kirin
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, potential future payment as percentage of certain amounts the Company receives under sublicense agreements																			30.00%									30.00%
Term of royalty payment obligations													12 years
Royalties on the net sales																												$ 4,700,000
Licensing Agreements | FDA Marketing Approval | Kyowa Kirin
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, milestone payment																$ 12,000,000
Research and development | Astra Zeneca Agreement | Astra Zeneca Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payments received and recorded as an increased (decreased) to expense pursuant to cost-sharing provisions																												$ 900,000	$ 1,100,000	$ 500,000